Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Innovent and Lilly Jointly Announce the NMPA Granted Marketing Approval for HALPRYZA® (Rituximab Injection) in China

prnasiaOctober 10, 2020

Tag: HALPRYZA , Innovent , Eli Lilly , NMPA

PharmaSources Customer Service